Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Otsuka Acquires Jnana and its Rare Disease Therapy in $1.1 Billion Agreement

publication date: Aug 1, 2024

Japan’s Otsuka Pharmaceutical acquired Jnana Therapeutics, a Boston pharma, for $800 million plus up to $325 million in milestones. Jnana is developing a novel therapy to treat phenylketonuria (PKU), a rare kidney disease. Jnana’s JNT-517 is an allosteric small-molecule inhibitor of SLC6A19, a solute carrier that regulates amino acid reabsorption in the kidney. It has completed a Phase Ib/II trial demonstrating its tolerability. Otsuka believes JNT-517 could be a first-in-class oral treatment for PKU. In 2018, Otsuka acquired another Boston company, Visterra, which develops antibody drugs for autoimmune diseases. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here